Method for determination of the status of a disease

Patent metadata

Field	Value
Publication number	US-2016348176-A1
Application number	US-201515116588-A
Country	US
Kind code	A1
Filing date	Jan 29, 2015
Priority date	Feb 6, 2014
Publication date	Dec 1, 2016
Grant date	—

Abstract

The present invention relates to a method for determining the state of peri-implant disease comprising the steps of quantifying the expression level of one or more regulated markers of a group of markers forming a panel, said one or more regulated markers being related to the plasminogen system and/or inflammation and/or proteolytic activity or combinations thereof or ratios thereof in an ex vivo sample; and determining the state of peri-implant disease by comparing the expression level obtained in step a with a reference value. The present invention also relates to a kit for performing the invention.

First claim

1 . A method for determining the state of peri-implant disease, wherein the method comprises the steps of:
a) quantifying the expression level of one or more regulated markers selected from the group consisting of tPA, IL-4, IL-6, IL-10, IL-12, IL18, TIMP-1 and PAI-2, or any combination thereof, or any ratio thereof; and/or quantifying the expression levels of one or more of the following combinations of markers: tPA and tPA/PAI-2; PAI-2 and tPA/PAI-2; tPA, PAI-2 and tPA/PAI-2; tPA and IL-1β; tPA and TIMP-1; IL-1β and IL-8; IL-8 and PAI-2; IL-6, TIMP-1 and PAI-2; tPA and PAI-2; IL-1β, IL-8 and IL-6; IL-1β, IL-8, IL-6 and TIMP-1; IL-1β, IL-8, IL-6, TIMP-1 and tPA; IL-1β, IL-8, IL-6, TIMP-1 and PAI-2; IL-1β, IL-8, PAI-2 and tPA; IL-1β, IL-8, and PAI-2; IL-1β, IL-8 and tPA; IL-1β, IL-8 and tPA/PAI-2; IL-1β, IL-8, TIMP-1 and PAI-2; IL-1β, IL-8, TIMP-1 and tPA; tPA/PAI-2; PAI-2/tPA; IL-1β and PAI-2; in an ex vivo sample; and b) determining the state of peri-implant disease by comparing the expression level obtained in step a) with one or more reference expression level(s).

2 . The method according to claim 1 , wherein said one or more regulated markers is selected from the group consisting of tPA and PAI-2, or any combination thereof, or any ratio thereof.

3 . The method according to claim 1 , wherein the expression level of the one or more regulated markers is the ratio between tPA and PAI-2.

4 . The method according to claim 1 , wherein said marker is tPA.

5 . The method according to claim 1 , wherein said one or more regulated markers is selected from the group consisting of IL-6, TIMP-1 and PAI-2, or any combination thereof, or any ratio thereof.

6 . The method according to claim 1 , wherein the ex vivo sample is a body fluid selected from an oral fluid, blood, serum, plasma, saliva or peri-implant crevicular fluid.

7 - 8 . (canceled)

9 . The method according to claim 16 , wherein the ex vivo sample is a tissue selected from bone, connective tissue, mucosa, implant supporting tissue, bone adjacent to an implant, or bone adjacent to a tooth.

10 . (canceled)

11 . The method according to claim 1 , wherein the one or more reference expression level(s) of step b) is the expression level(s) of said one or more regulated markers, or any combination thereof, or any ratio thereof from an ex vivo sample taken from the same source at a different point in time, and wherein an up-regulation or down-regulation of the expression levels of said one or more regulated markers, or any combination thereof, or any ratio thereof compared with the one or more reference expression level(s) is indicative of the state of peri-implant disease.

12 . The method according to claim 1 , wherein the one or more reference expression level(s) of step b) is the expression level of said one or more regulated markers, or any combination thereof, or any ratio thereof, from an ex vivo sample taken from a source showing a history of peri-implantitis, and wherein the up-regulation or down-regulation of the expression levels of said one or more regulated markers, or combination thereof, or ratio thereof compared with the one or more reference expression level(s) is indicative of the state of peri-implant disease.

13 . The method according to claim 1 , wherein quantifying the expression level is performed by a method for nucleic acid quantification selected from qPCR or Northern Blot.

14 . (canceled)

15 . The method according to claim 1 , wherein quantifying the expression level is performed by a method for protein quantification selected from immunoassay, ELISA, radioimmunoassay, magnetic immunoassay, fluorescent immunoassay, immunoprecipitation, surface plasmon resonance, immunohistochemistry, Western Blot, or any combination thereof.

16 . (canceled)

17 . The method according to claim 1 , wherein the ex vivo sample is obtained from a patient who has one or more implants, selected from a bone anchored implant, a dental implant, a hip implant, a knee implant, or a combination thereof.

18 - 19 . (canceled)

20 . The method according to claim 1 , further comprising the step of saving the information regarding expression level of one or more regulated markers obtained in step (a) and/or saving the information regarding the state of peri-implant disease obtained in step (b) in a data carrier.

21 . A kit for carrying out the method according to claim 1 .

22 . The kit according to claim 21 , wherein the kit comprises a sample collecting device, selected from a sterile paper point, a syringe, or a biopsy device.

23 . (canceled)

24 . The kit according to claim 21 , wherein the kit further comprises a preservation medium for preserving the sample.

25 . The kit according to claim 21 , wherein the kit further contains a box to send the sample to a central laboratory.

26 . The kit according to claim 21 , wherein the kit further contains the necessary elements to quantify the expression levels of one or more markers selected from the group consisting of IL-4, IL-6, IL-10, IL-12, IL18, TIMP-1, tPA and PAI-2 or any combination thereof, or any ratio thereof, or the necessary elements to quantify the expression levels of the following combinations of markers: tPA and tPA/PAI-2; PAI-2 and tPA/PAI-2; tPA, PAI-2 and tPA/PAI-2; tPA and IL-1β; tPA and TIMP-1; IL-1β and IL-8; IL-8 and PAI-2; IL-6, TIMP-1 and PAI-2; tPA and PAI-2; IL-1β, IL-8 and IL-6; IL-1β, IL-8, IL-6 and TIMP-1; IL-1β, IL-8, IL-6, TIMP-1 and tPA; IL-1β, IL-8, IL-6, TIMP-1 and PAI-2; IL-1β, IL-8, PAI-2 and tPA; IL-1β, IL-8, and PAI-2; IL-1β, IL-8 and tPA; IL-1β, IL-8 and tPA/PAI-2; IL-1β, IL-8, TIMP-1 and PAI-2; IL-1β, IL-8, TIMP-1 and tPA; tPA/PAI-2; PAI-2/tPA; IL-1β and PAI-2; or the necessary elements to quantify the expression levels of the following ratio of markers; tPA/PAI-2.

27 . The kit according to claim 26 , wherein said marker is tPA.

28 . The kit according to claim 21 , further comprising a data carrier.

Assignees

• Nobel Biocare Services Ag

Inventors

• Hall Jan

Classifications

• G01N2800/18

  Dental and oral disorders · CPC title

• G01N2333/8146

  Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP · CPC title

• G01N2333/811

  Serine protease (E.C. 3.4.21) inhibitors · CPC title

• G01N2333/5412

  IL-6 · CPC title

• G01N33/6869 Primary

  Interleukin · CPC title